A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil

Trial Profile

A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs PF 5212377 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 21 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 21 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top